Inclusion Criteria:

          1. Patients with advanced or metastatic cancer that is refractory to standard therapy or
             that has relapsed after standard therapy or has no standard therapy that increases
             survival by at least three months.

          2. All prior treatment- related toxicities must be CTCAE (Version 4.0) less than or equal
             to Grade 2 (except alopecia) at the time of screening however clinically relevant AEs
             that will impact on the ADE of the study drugs or safety of the subject must have
             resolved to Grade 1 or better.

          3. Adequate baseline organ function defined as following: Absolute neutrophil count
             greater than or equal to 1.5 x 109 cells/L, hemoglobin greater than or equal to 8.0
             g/dL, platelets greater than or equal to 75 x 109/L, creatinine less than or equal to
             1.5 X upper limit of normal (ULN) with calculated creatinine clearance greater than 30
             ml/min, total bilirubin less than or equal to 1.5 X ULN, AST(SGOT) and/or ALT(SGPT)
             less than or equal to 3 XULN.

          4. 18 years of age or older.

          5. Life expectancy of at least 3 months in the opinion of investigator.

          6. Able to swallow and retain orally administered medication and does not have any
             clinically significant gastrointestinal abnormalities that may alter absorption such
             as malabsorption syndrome or major resection of the stomach or bowels.

          7. Measurable disease as defined by RECIST criteria (Version 1.1).

          8. Patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or
             1.

          9. Having archival paraffin tissue is ideal for the correlative study but it is not
             mandatory.

         10. Voluntary written consent must be given before performance of any study related
             procedure not part of standard medical care, with the understanding that consent may
             be withdrawn by the patient at any time without prejudice to future medical care.

         11. Female patients who: Are postmenopausal for at least 1 year before the screening
             visit, OR Are surgically sterile, OR If they are of childbearing potential, agree to
             practice 2 effective methods of contraception, at the same time, from the time of
             signing the informed consent form through 90 days after the last dose of study drug,
             OR Agree to practice true abstinence when this is in line with the preferred and usual
             lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation,
             symptothermal, post-ovulation methods]), And latex or non-latex condom with or without
             a spermicidal agent, Diaphragm with spermicide; Cervical cap with a spermicide; Sponge
             with a spermicide

         12. Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree
             to one of the following: a) Agree to practice effective barrier contraception during
             the entire study treatment period and through 90 days after the last dose of study
             drug, OR b) Latex or non-latex condom with or without a spermicidal agent, Diaphragm
             with spermicide; Cervical cap with a spermicide; Sponge with a spermicide.

         13. Inclusion Criteria for dose expansion cohort: Non-small cell lung cancer: 1) We will
             enroll non-small cell lung cancer patients with documented EGFR mutation who failed
             treatment with anti-EGFR therapy (e.g. erlotinib or afatinib) and tested negative for
             EGFR T790M mutation. We will allow patients with positive EGFR T790M mutation if they
             have progressed on third generation anti-EGFR therapy (e.g. CO-1686 or AZD9291) or
             medically not suitable/candidate for the third generation anti-EGFR therapy. Failure
             from anti-EGFR therapy will be defined as progressive disease by RECIST (Version 1.1)
             after at least two months of therapy. We plan to enroll up to 9 patients in this
             cohort.

         14. Pancreatic ductal adenocarcinoma: 1) Pancreatic ductal adenocarcinoma patient with
             KRAS point mutation at codon G12 or G13. Since KRAS mutation is present in more than
             90% of pancreatic cancer with 98% of the mutation found at codon 12, we expect
             majority of patients with pancreatic ductal adenocarcinoma will be eligible for the
             study. We plan to enroll up to 9 patients in this cohort. In addition to the above
             inclusion criteria, first 5 patients from both non-small cell lung cancer and
             pancreatic ductal adenocarcinoma patients will need to agree to mandatory pre- and
             post-treatment tumor biopsies.

        Exclusion Criteria:

          1. Any serious and/or unstable pre-existing medical disorder (aside from malignancy
             exception above), psychiatric disorder, or other conditions that could interfere with
             subject's safety, obtaining informed consent or compliance to the study procedures, in
             the opinion of the Investigator.

          2. Radiotherapy completed within 2 weeks prior to treatment initiation. Radiotherapy
             completed >2 weeks prior to treatment initiation is allowed if all procedure-related
             toxicities resolved per inclusion #2.

          3. Patient who were receiving prior therapy will require wash out period of either more
             than 2 weeks or more than 5 half-lives whichever shorter.

          4. Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO).

          5. Current use of a prohibited medication.

          6. Symptomatic or untreated leptomeningeal or brain metastases or spinal cord
             compression. If these were treated and clinically stable for 4 weeks, patient can be
             considered for the trial.

          7. Patient who is on strong inducer/inhibitor of CYP3A needs to be off the medication
             prior to treatment initiation unless it is medically necessary for the patient.

          8. Female patients who are lactating or have a positive serum pregnancy test suggestive
             of pregnancy and not as a tumor marker during the screening period. If pregnancy is
             tested positive, treating physician will further investigate if the patient is
             pregnant or not. Treating physician may consider repeating the serum beta-hCG at next
             follow up visit or refer patient to OB/GYN for further evaluation.

          9. Major surgery within 14 days before enrollment.

         10. Infection requiring systemic antibiotic therapy or other serious infection within 14
             days before study enrollment.

         11. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled
             hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure,
             unstable angina, or myocardial infarction within the past 6 months.

         12. Ongoing or active systemic infection, active hepatitis B or C virus infection, or
             known human immunodeficiency virus (HIV) positive.

         13. Diagnosed or treated for another malignancy within 2 years before study enrollment or
             previously diagnosed with another malignancy and have any evidence of residual
             disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are
             not excluded if they have undergone complete resection.

         14. Patient has greater than or equal than Grade 2 peripheral neuropathy, or Grade 1 with
             pain on clinical examination during the screening period.

         15. Patients that have previously been treated with ixazomib, or participated in a study
             with ixazomib whether treated with ixazomib or not.